Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: A Systematic Review and Pooled Meta-analysis.
Biologic
IBD
Inflammatory Bowel Diseases
RCT
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
16
01
2020
revised:
11
06
2020
accepted:
15
06
2020
pubmed:
23
6
2020
medline:
19
8
2021
entrez:
23
6
2020
Statut:
ppublish
Résumé
It is not clear whether concomitant therapy with corticosteroids and anti-tumor necrosis factor (TNF) agents is more effective at inducing remission in patients with Crohn's disease (CD) than anti-TNF monotherapy. We aimed to determine whether patients with active CD receiving corticosteroids during induction therapy with anti-TNF agents had higher rates of clinical improvement than patients not receiving corticosteroids during induction therapy. We systematically searched the MEDLINE, Embase, and CENTRAL databases, through January 20, 2016, for randomized trials of anti-TNF agents approved for treatment of CD and identified 14 trials (5 of adalimumab, 5 of certolizumab, and 4 of infliximab). We conducted a pooled meta-analysis of individual patient and aggregated data from these trials. We compared data from participants who continued oral corticosteroids during induction with anti-TNF therapy to those treated with anti-TNF agents alone. The endpoints were clinical remission (CD activity index [CDAI] scores <150) and clinical response (a decrease in CDAI of 100 points) at the end of induction (weeks 4-14 of treatment). We included 4354 patients who received induction therapy with anti-TNF agents, including 1653 [38.0%] who were receiving corticosteroids. The combination of corticosteroids and an anti-TNF agent induced clinical remission in 32.0% of patients, whereas anti-TNF monotherapy induced clinical remission in 35.5% of patients (odds ratio [OR], 0.93; 95% CI, 0.74-1.17). The combination of corticosteroids and an anti-TNF agent induced a clinical response in 42.7% of patients, whereas anti-TNF monotherapy induced a clinical response in 46.8% (OR 0.84; 95% CI, 0.73-0.96). These findings did not change with adjustment for baseline CDAI scores and concurrent use of immunomodulators. Based on a meta-analysis of data from randomized trials of anti-TNF therapies in patients with active CD, patients receiving corticosteroids during induction therapy with anti-TNF agents did not have higher rates of clinical improvement compared with patients not receiving corticosteroids during induction therapy. Given these findings and the risks of corticosteroid use, clinicians should consider early weaning of corticosteroids during induction therapy with anti-TNF agents for patients with corticosteroid-refractory CD.
Sections du résumé
BACKGROUND & AIMS
It is not clear whether concomitant therapy with corticosteroids and anti-tumor necrosis factor (TNF) agents is more effective at inducing remission in patients with Crohn's disease (CD) than anti-TNF monotherapy. We aimed to determine whether patients with active CD receiving corticosteroids during induction therapy with anti-TNF agents had higher rates of clinical improvement than patients not receiving corticosteroids during induction therapy.
METHODS
We systematically searched the MEDLINE, Embase, and CENTRAL databases, through January 20, 2016, for randomized trials of anti-TNF agents approved for treatment of CD and identified 14 trials (5 of adalimumab, 5 of certolizumab, and 4 of infliximab). We conducted a pooled meta-analysis of individual patient and aggregated data from these trials. We compared data from participants who continued oral corticosteroids during induction with anti-TNF therapy to those treated with anti-TNF agents alone. The endpoints were clinical remission (CD activity index [CDAI] scores <150) and clinical response (a decrease in CDAI of 100 points) at the end of induction (weeks 4-14 of treatment).
RESULTS
We included 4354 patients who received induction therapy with anti-TNF agents, including 1653 [38.0%] who were receiving corticosteroids. The combination of corticosteroids and an anti-TNF agent induced clinical remission in 32.0% of patients, whereas anti-TNF monotherapy induced clinical remission in 35.5% of patients (odds ratio [OR], 0.93; 95% CI, 0.74-1.17). The combination of corticosteroids and an anti-TNF agent induced a clinical response in 42.7% of patients, whereas anti-TNF monotherapy induced a clinical response in 46.8% (OR 0.84; 95% CI, 0.73-0.96). These findings did not change with adjustment for baseline CDAI scores and concurrent use of immunomodulators.
CONCLUSIONS
Based on a meta-analysis of data from randomized trials of anti-TNF therapies in patients with active CD, patients receiving corticosteroids during induction therapy with anti-TNF agents did not have higher rates of clinical improvement compared with patients not receiving corticosteroids during induction therapy. Given these findings and the risks of corticosteroid use, clinicians should consider early weaning of corticosteroids during induction therapy with anti-TNF agents for patients with corticosteroid-refractory CD.
Identifiants
pubmed: 32569749
pii: S1542-3565(20)30847-8
doi: 10.1016/j.cgh.2020.06.036
pmc: PMC8364422
mid: NIHMS1724737
pii:
doi:
Substances chimiques
Steroids
0
Tumor Necrosis Factor Inhibitors
0
Tumor Necrosis Factor-alpha
0
Infliximab
B72HH48FLU
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
238-245.e4Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.
Références
Am J Gastroenterol. 2012 Sep;107(9):1409-22
pubmed: 22890223
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
N Engl J Med. 2007 Jul 19;357(3):239-50
pubmed: 17634459
Ann Intern Med. 2007 Nov 20;147(10):699-702
pubmed: 18025446
Clin Gastroenterol Hepatol. 2019 Apr;17(5):818-823
pubmed: 30196164
BMJ. 2017 Jun 19;357:j2505
pubmed: 28630047
Inflamm Bowel Dis. 2014 Apr;20(4):622-30
pubmed: 24583478
Lancet. 2002 May 4;359(9317):1541-9
pubmed: 12047962
Ann Intern Med. 2007 Jun 19;146(12):829-38
pubmed: 17470824
Gastroenterology. 2005 Sep;129(3):807-18
pubmed: 16143120
Gastroenterology. 2012 May;142(5):1102-1111.e2
pubmed: 22326435
N Engl J Med. 2010 Apr 15;362(15):1383-95
pubmed: 20393175
N Engl J Med. 1999 May 6;340(18):1398-405
pubmed: 10228190
Am J Gastroenterol. 2002 Apr;97(4):803-23
pubmed: 12003413
Gastroenterology. 1979 Oct;77(4 Pt 2):847-69
pubmed: 38176
N Engl J Med. 2007 Jul 19;357(3):228-38
pubmed: 17634458
Gastroenterology. 2007 Jan;132(1):52-65
pubmed: 17241859
JAMA. 2011 Dec 7;306(21):2331-9
pubmed: 22056398
Mayo Clin Proc. 2008 Feb;83(2):181-94
pubmed: 18241628
Gastroenterology. 2014 Mar;146(3):681-688.e1
pubmed: 24269926
Clin Gastroenterol Hepatol. 2010 Aug;8(8):688-695.e2
pubmed: 20451663
Am J Gastroenterol. 2011 Apr;106(4):590-9; quiz 600
pubmed: 21407179
Gastroenterology. 2006 Feb;130(2):323-33; quiz 591
pubmed: 16472588
PLoS One. 2016 Jun 23;11(6):e0158017
pubmed: 27336296
J Crohns Colitis. 2012 Mar;6(2):160-73
pubmed: 22325170
Clin Gastroenterol Hepatol. 2011 Aug;9(8):670-678.e3
pubmed: 21642014
Lancet. 2017 Apr 29;389(10080):1741-1755
pubmed: 27914655
Aliment Pharmacol Ther. 2002 Jan;16(1):51-60
pubmed: 11856078
Ann Intern Med. 2019 Jan 15;170(2):99-107
pubmed: 30534946
Am J Gastroenterol. 2018 Mar;113(3):405-417
pubmed: 29336432
Gastroenterology. 2006 Apr;130(4):1054-61
pubmed: 16618399
N Engl J Med. 2004 Feb 26;350(9):876-85
pubmed: 14985485
Am J Gastroenterol. 2016 Dec;111(12):1806-1815
pubmed: 27670599
BMJ. 2011 Jul 22;343:d4002
pubmed: 21784880
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120